0001209191-24-002074.txt : 20240123
0001209191-24-002074.hdr.sgml : 20240123
20240123165839
ACCESSION NUMBER: 0001209191-24-002074
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230711
FILED AS OF DATE: 20240123
DATE AS OF CHANGE: 20240123
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Overdorf Michael
CENTRAL INDEX KEY: 0001818522
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39402
FILM NUMBER: 24553268
MAIL ADDRESS:
STREET 1: C/O ANNEXON, INC.
STREET 2: 180 KIMBALL WAY, SUITE 200
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Annexon, Inc.
CENTRAL INDEX KEY: 0001528115
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 275414423
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1400 SIERRA POINT PARKWAY
STREET 2: BLDG C, SUITE 200
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: (650)-822-5500
MAIL ADDRESS:
STREET 1: 1400 SIERRA POINT PARKWAY
STREET 2: BLDG C, SUITE 200
CITY: BRISBANE
STATE: CA
ZIP: 94005
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-07-11
0
0001528115
Annexon, Inc.
ANNX
0001818522
Overdorf Michael
C/O ANNEXON, INC.
1400 SIERRA POINT PKWY, BLDG C, STE 200
BRISBANE
CA
94005
0
1
0
0
EVP & Chief Business Officer
0
Common Stock
2023-07-11
4
S
0
978
3.8361
D
45802
D
The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").
This transaction was executed in multiple trades in prices ranging from $3.72 to $3.90, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Includes 33,559 RSUs.
Late filing being made as a result of an administrative oversight.
/s/ Jennifer Lew, as Attorney-in-Fact
2024-01-23